

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

April 25, 2017  
(Date of earliest event reported)

**LABORATORY CORPORATION OF  
AMERICA HOLDINGS**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**

**1-11353**

**13-3757370**

(State or other jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

**358 South Main Street,  
Burlington, North Carolina**

**27215**

**336-229-1127**

(Address of principal executive offices)

(Zip Code)

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether registrant is an emerging growth company as defined in Rule 405 of Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure

Summary information of the Company dated April 25, 2017.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

Registrant

By: /s/ F. SAMUEL EBERTS III  
F. Samuel Eberts III  
Chief Legal Officer and Secretary

April 25, 2017



**FIRST QUARTER 2017  
SUPPLEMENTAL FINANCIAL INFORMATION**

8-K FILED APRIL 25, 2017

## FORWARD LOOKING STATEMENT

**This presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers.**

**Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the operating and financial results of Laboratory Corporation of America Holdings (the “Company”) is included in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.**

## USE OF ADJUSTED MEASURES

The Company has provided in this presentation “adjusted” financial information that has not been prepared in accordance with GAAP, including Adjusted EPS, Adjusted Operating Income, Free Cash Flow, and certain segment information. The Company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the Company’s operational performance. The Company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the Company’s financial results with the financial results of other companies. However, the Company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are included in the tables accompanying this presentation.

### **LabCorp Diagnostics**

The LabCorp Diagnostics segment includes historical LabCorp business units, excluding its Clinical Trials operations (which are part of the Covance Drug Development segment), and including the Nutritional Chemistry and Food Safety operations acquired as part of the Covance acquisition.

### **Covance Drug Development**

The Covance Drug Development segment includes historical Covance business units, excluding its Nutritional Chemistry and Food Safety operations (which are part of the LabCorp Diagnostics segment), and including the LabCorp Clinical Trials operations.

## FIRST QUARTER CONSOLIDATED RESULTS

(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)

	<u>1Q17</u>	<u>1Q16</u>	<u>% Change</u>
Net Revenue	\$2,408.1	\$2,295.2	4.9%
Adjusted Operating Income <sup>(1) (2)</sup>	\$391.3	\$373.1	4.9%
<i>Adjusted Operating Margin</i>	16.2%	16.3%	(10 bps)
Adjusted EPS <sup>(1) (2)</sup>	\$2.22	\$2.05	8.3%
Operating Cash Flow	\$233.8	\$127.6	83.2%
Less: Capital Expenditures	(\$ 72.2)	(\$ 71.4)	(1.1%)
Free Cash Flow	\$161.6	\$ 56.2	187.5%

(1) Adjusted Operating Income and Adjusted EPS exclude amortization, restructuring charges and special items

(2) See Reconciliation of non-GAAP Financial Measures on slides 13 – 16

## FIRST QUARTER PRO FORMA SEGMENT RESULTS<sup>(1)</sup>

(DOLLARS IN MILLIONS)

	<u>1Q17</u>	<u>1Q16</u>	<u>% Change</u>
<b>Net Revenue</b>			
LabCorp Diagnostics	\$1,717.9	\$1,590.6	8.0%
Covance Drug Development <sup>(2)</sup>	\$690.3	\$703.1	(1.8%)
<b>Total Net Revenue<sup>(2)</sup></b>	<b>\$2,408.1</b>	<b>\$2,293.6</b>	<b>4.9%</b>
<b>Adjusted Operating Income<sup>(3) (4)</sup></b>			
LabCorp Diagnostics	\$341.0	\$308.0	10.7%
<i>Adjusted Operating Margin</i>	<i>19.9%</i>	<i>19.4%</i>	<i>50 bps</i>
Covance Drug Development	\$83.5	\$103.2	(19.1%)
<i>Adjusted Operating Margin</i>	<i>12.1%</i>	<i>14.7%</i>	<i>(260 bps)</i>
Unallocated Corporate Expense	(\$33.2)	(\$38.0)	12.6%
<b>Total Adjusted Operating Income</b>	<b>\$391.3</b>	<b>\$373.1</b>	<b>4.9%</b>
<i>Total Adjusted Operating Margin</i>	<i>16.2%</i>	<i>16.3%</i>	<i>(10 bps)</i>

(1) The consolidated net revenue and adjusted operating income are presented net of inter-segment transaction eliminations

(2) Covance Drug Development's results exclude the impact from the wind-down of operations relating to a committed minimum volume contract that expired on October 31, 2015

(3) Adjusted Operating Income excludes amortization, restructuring charges and special items

<sup>5</sup> (4) See Reconciliation of non-GAAP Financial Measures on slides 13 – 16





## SELECT FINANCIAL METRICS

(DOLLARS IN MILLIONS)

	<u>1Q16</u>	<u>2Q16</u>	<u>3Q16</u>	<u>4Q16</u>	<u>1Q17</u>
Total Depreciation	\$75.9	\$77.9	\$78.0	\$79.3	\$78.4
Total Amortization <sup>(1)</sup>	\$44.3	\$45.3	\$41.1	\$48.8	\$47.6
Total Adjusted EBITDA <sup>(2)</sup>	\$450.8	\$505.4	\$485.0	\$469.3	\$472.2
Total Debt to Last Twelve Months Adjusted EBITDA <sup>(2)</sup>	3.5x	3.3x	3.3x	3.1x	3.1x
Total Net Debt to Last Twelve Months Adjusted EBITDA <sup>(2)</sup>	3.1x	2.9x	3.0x	2.9x	2.9x

(1) Excludes amortization of deferred financing fees

(2) Adjusted EBITDA excludes restructuring charges and special items. See reconciliation on slide 12.

## COVANCE DRUG DEVELOPMENT: SELECT FINANCIAL METRICS<sup>(1)</sup>

### Trailing Twelve Month (TTM) Results


	Net Orders	Net Book-to-Bill
TTM Ending March 31, 2017	\$3.2 billion	1.15x
TTM Ending December 31, 2016	\$3.1 billion	1.11x

	Backlog	Estimated revenue expected to convert from backlog in the next twelve months
As of March 31, 2017	\$5.2 billion	\$2.1 billion
As of December 31, 2016	\$4.9 billion	\$2.0 billion


(1) Beginning with the fourth quarter of 2016, the Company began reporting net orders, net book-to-bill and backlog based upon fully-executed contracted awards. The Company believes this methodology is a more conservative and objective practice, providing greater visibility into its revenue conversion from the backlog. Results shown include the impact from cancellations and foreign currency translation.

## FIRST QUARTER 2017 NET REVENUE DISTRIBUTION

**Segment Distribution**



**Geographic Distribution**



(1) Revenues recognized in over 30 currencies; the largest foreign currency accounts for less than 10% of total net revenue

## FIRST QUARTER 2017 FOREIGN EXCHANGE IMPACT TO NET REVENUE

(DOLLARS IN MILLIONS)

	<u>Dollars</u>	<u>Year over Year % Growth</u>
<b><u>Consolidated</u></b>		
Net Revenue, as Reported	\$2,408	4.9%
Foreign Exchange Impact	\$9	0.4%
Net Revenue, Constant Currency	\$2,417	5.3%
<b><u>LabCorp Diagnostics</u></b>		
Net Revenue, as Reported	\$1,718	8.0%
Foreign Exchange Impact	(\$1)	(0.1%)
Net Revenue, Constant Currency	\$1,717	7.9%
<b><u>Covance Drug Development</u></b>		
Net Revenue, as Reported	\$690	(1.8%)
Foreign Exchange Impact	\$11	1.5%
Net Revenue, Constant Currency	\$701	(0.3%)

## 2017 FINANCIAL GUIDANCE

	<b>Prior Guidance</b> (assumes foreign exchange rates effective as of December 31, 2016)	<b>Current Guidance</b> (assumes foreign exchange rates effective as of March 31, 2017)
Total net revenue growth:	4.5% – 6.5% <sup>(2)</sup>	3.5% – 5.5% <sup>(3)</sup>
LabCorp Diagnostics net revenue growth:	4.5% – 6.5% <sup>(4)</sup>	5.0% – 7.0% <sup>(5)</sup>
Covance Drug Development net revenue growth:	3.5% – 5.5% <sup>(6)</sup>	0.0% – 2.0% <sup>(7)</sup>
Adjusted EPS <sup>(1)</sup> :	\$9.35 – \$9.75	\$9.20 – \$9.60
Free cash flow:	\$925 Million – \$975 Million	\$925 Million – \$975 Million

(1) Excludes the impact from amortization, restructuring charges and special items.

(2) Included the impact from approximately 60 basis points of negative currency.

(3) Includes the impact from approximately 40 basis points of negative currency.

(4) Included the impact from approximately 10 basis points of negative currency.

(5) Includes the impact from approximately 10 basis points of negative currency.

(6) Included the impact from approximately 180 basis points of negative currency.

(7) Includes the impact from approximately 130 basis points of negative currency.

## 2016 QUARTERLY RESULTS<sup>(1)</sup>

(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)

	2016				
	1Q	2Q	3Q	4Q	Full-Year
<b>LabCorp Diagnostics</b>					
Net Revenue	\$1,590.6	\$1,659.7	\$1,671.8	\$1,671.8	\$6,593.9
Adjusted Operating Income (2)	\$308.0	\$355.3	\$341.8	\$317.8	\$1,322.9
Adjusted Operating Margin (2)	19.4%	21.4%	20.4%	19.0%	20.1%
<b>Covance Drug Development</b>					
Net Revenue	\$703.1	\$722.4	\$701.1	\$715.6	\$2,842.2
Adjusted Operating Income (2)	\$103.2	\$107.5	\$95.5	\$106.5	\$412.7
Adjusted Operating Margin (2)	14.7%	14.9%	13.6%	14.9%	14.5%
<b>Consolidated</b>					
Net Revenue	\$2,293.6	\$2,382.0	\$2,372.7	\$2,387.3	\$9,435.6
Adjusted Segment Operating Income (2)	\$411.1	\$462.8	\$437.3	\$424.3	\$1,735.6
Unallocated Corporate Expenses	(\$38.0)	(\$37.6)	(\$33.3)	(\$36.5)	(\$145.4)
Consolidated Adjusted Operating Income (2)	\$373.1	\$425.2	\$404.0	\$387.8	\$1,590.1
Adjusted Operating Margin (2)	16.3%	17.9%	17.0%	16.2%	16.9%
Adjusted EPS (3)	\$2.05	\$2.37	\$2.25	\$2.15	\$8.83

(1) The consolidated net revenue and adjusted operating income are presented net of inter-segment transaction eliminations. Reconciliations of non-GAAP financial measures were filed with the SEC on April 25, 2016, July 27, 2016, October 26, 2016 and February 16, 2017

(2) Adjusted Operating Income and Margin exclude amortization, restructuring charges and special items. In addition, during the third quarter of 2016, the Company reclassified certain gross receipts taxes from its provision for income taxes to selling, general and administrative expenses. This revision impacts Adjusted Operating Income and Margin and was made for all periods presented, as shown. These adjustments had no impact on reported net income or EPS.

(3) Adjusted EPS exclude amortization, restructuring charges and special items. In addition, Adjusted EPS exclude amortization, restructuring charges and special items. In the third quarter of 2016, the Company adopted the provision of the new FASB Accounting Standard on Share-Based Payment Accounting. The standard requires that companies recognize all income tax impacts of share-based payments in their provision for income taxes. Before adoption, this impact had been recorded as an adjustment of the Company's income tax liability and additional paid-in capital. The new standard also eliminates the use of estimated income tax impacts in the calculation of common stock equivalents in determining dilutive shares outstanding. Per the guidance in the new standard, the Company applied the standard retroactively to the beginning of 2016.

## RECONCILIATION OF NON-GAAP FINANCIAL MEASURES – ADJUSTED EBITDA (DOLLARS IN MILLIONS)

	<u>1Q16</u>	<u>2Q16</u>	<u>3Q16</u>	<u>4Q16</u>	<u>1Q17</u>
LabCorp Operating Income	\$299.5	\$365.5	\$324.0	\$323.4	\$332.7
Add:					
Restructuring and other special charges	\$19.2	\$6.6	\$22.8	\$9.8	\$3.9
Other special charges <sup>(1)</sup>	\$10.1	\$7.9	\$16.1	\$5.8	\$7.1
Depreciation	\$75.9	\$77.9	\$77.9	\$79.3	\$78.4
Amortization	\$44.3	\$45.3	\$41.1	\$48.8	\$47.6
Equity method income, net	\$1.4	\$1.9	\$2.6	\$2.0	\$2.3
Depreciation and amortization of equity method investments	\$0.4	\$0.3	\$0.5	\$0.2	\$0.2
Adjusted EBITDA	\$450.8	\$505.4	\$485.0	\$469.3	\$472.2

(1) Other special charges as disclosed by the Company in its quarterly earnings releases

## RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

### LABORATORY CORPORATION OF AMERICA HOLDINGS

#### Reconciliation of Non-GAAP Financial Measures

(in millions, except per share data)

	Three Months Ended March 31,	
	2017	2016
<b><u>Adjusted Operating Income</u></b>		
Operating Income	\$ 332.7	\$ 299.5
Acquisition-related costs	4.4	2.9
Restructuring and other special charges	3.9	19.2
Consulting fees and executive transition expenses	-	4.1
Wind-down of minimum volume contract operations	-	1.6
LaunchPad system implementation costs	2.7	1.5
Amortization of intangibles and other assets	47.6	44.3
Adjusted operating income	<u>\$ 391.3</u>	<u>\$ 373.1</u>
<b><u>Adjusted EPS</u></b>		
Diluted earnings per common share	\$ 1.84	\$ 1.58
Restructuring and special items	0.07	0.18
Amortization expense	0.31	0.29
Adjusted EPS	<u>\$ 2.22</u>	<u>\$ 2.05</u>



## RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

### LABORATORY CORPORATION OF AMERICA HOLDINGS

#### Reconciliation of Non-GAAP Financial Measures

(in millions, except per share data)

	Three Months Ended March 31,	
	2017	2016
<b><u>Free Cash Flow:</u></b>		
Net cash provided by operating activities	\$ 233.8	\$ 127.6
Less: Capital expenditures	(72.2)	(71.4)
Free cash flow	<u>\$ 161.6</u>	<u>\$ 56.2</u>

## RECONCILIATION OF NON-GAAP FINANCIAL MEASURES - FOOTNOTES

1) During the first quarter of 2017, the Company recorded net restructuring and other special charges of \$3.9 million. The charges included \$2.7 million in severance and other personnel costs along with \$1.6 million in costs associated with facility closures and general integration initiatives. The Company reversed previously established reserves of \$0.4 million in unused severance reserves.

The Company incurred legal and other costs of \$0.9 million relating to the recently completed acquisitions. The Company also recorded \$2.6 million in consulting expenses relating to fees incurred as part of its Covance integration costs and compensation analysis, along with \$0.9 million in short-term equity retention arrangements relating to the acquisition of Covance. In addition, the Company incurred \$2.7 million of non-capitalized costs associated with the implementation of a major system as part of its LaunchPad business process improvement initiative (all recorded in selling, general and administrative expenses).

The after tax impact of these charges decreased net earnings for the quarter ended March 31, 2017, by \$6.9 million and diluted earnings per share by \$0.07 (\$6.9 million divided by 104.3 million shares).

## RECONCILIATION OF NON-GAAP FINANCIAL MEASURES - FOOTNOTES

2) During the first quarter of 2016, the Company recorded net restructuring and other special charges of \$19.2 million. The charges included \$4.5 million in severance and other personnel costs along with \$17.0 million in costs associated with facility closures and general integration initiatives. A substantial portion of these costs relate to the planned closure of duplicative data center operations. The Company reversed previously established reserves of \$2.3 million in unused severance reserves primarily as the result of selling one of its minimum volume contract facilities to a third party.

The Company incurred additional legal and other costs of \$1.6 million relating to the wind-down of its minimum volume contract operations. The Company also recorded \$1.7 million in consulting expenses relating to fees incurred as part of its Covance integration costs and compensation analysis, along with \$1.2 million in short-term equity retention arrangements relating to the acquisition of Covance and \$4.1 million of accelerated equity compensation relating to the announced retirement of a Company executive. In addition, the Company incurred \$1.5 million of non-capitalized costs associated with the implementation of a major system as part of its LaunchPad business process improvement initiative (all recorded in selling, general and administrative expenses).

The after tax impact of these charges decreased net earnings for the quarter ended March 31, 2016, by \$19.0 million and diluted earnings per share by \$0.18 (\$19.0 million divided by 103.6 million shares).

3) The Company continues to grow the business through acquisitions and uses Adjusted EPS Excluding Amortization as a measure of operational performance, growth and shareholder returns. The Company believes adjusting EPS for amortization provides investors with better insight into the operating performance of the business. For the quarters ended March 31, 2017 and 2016, intangible amortization was \$47.6 million and \$44.3 million, respectively (\$32.4 million and \$30.1 million net of tax, respectively) and decreased EPS by \$0.31 (\$32.4 million divided by 104.3 million shares) and \$0.29 (\$30.1 million divided by 103.8 million shares), respectively.

